Comparison of tumor and normal tissue dose for accelerated partial breast irradiation using an electronic brachytherapy eBx source and an Iridium-192 source.

The objective of this study has been to compare treatment plans for patients treated with electronic brachytherapy (eBx) using the Axxent System as adjuvant therapy for early stage breast cancer with treatment plans prepared from the same CT image sets using an Ir-192 source. Patients were implanted with an appropriately sized Axxent balloon applicator based on tumor cavity size and shape. A CT image of the implanted balloon was utilized for developing both eBx and Ir-192 brachytherapy treatment plans. The prescription dose was 3.4 Gy per fraction for 10 fractions to be delivered to 1 cm beyond the balloon surface. Iridium plans were provided by the sites on 35 of the 44 patients enrolled in the study. The planning target volume coverage was very similar when comparing sources for each patient as well as between patients. There were no statistical differences in mean %V100. The percent of the planning target volume in the high dose region was increased with eBx as compared with Iridium (p < 0.001). The mean maximum calculated skin and rib doses did not vary greatly between eBx and Iridium. By contrast, the doses to the ipsilateral lung and the heart were significantly lower with eBx as compared with Iridium (p < 0.0001). The total nominal dwell times required for treatment can be predicted by using a combination of the balloon fill volume and planned treatment volume (PTV). This dosimetric comparison of eBx and Iridium sources demonstrates that both forms of balloon-based brachytherapy provide comparable dose to the planning target volume. Electronic brachytherapy is significantly associated with increased dose at the surface of the balloon and decreased dose outside the PTV, resulting in significantly increased tissue sparing in the heart and ipsilateral lung.

Automating the initial physics chart checking process.

The initial physics chart check, an essential quality assurance process, verifies that the physician intent is properly expressed in the treatment plan, the treatment plan is reasonable, and the Record and Verify (RV) system properly captures the plan parameters. In this work the process was automated by characterizing the initial physics chart check as a universal set of steps, compartmentalized into intra-plan and inter-plan reviews. The intra-plan review confirms the diagnosis-prescription-plan correlation, and verifies transfer accuracy of the signed treatment plan parameters into the RV system. The inter-plan review tabulates all RV parameters for similar cases, and highlights outliers. The tabulation of RV parameters for similar cases enables a summation of experience across staff members, and facilitates a comparison using the Statistical Process Control (SPC) formalism. A summary sheet, added to each reviewed chart, automatically documents deviations noted during the review process. Forty-five patient charts were analyzed using the software. The length of time for the entire initial chart-checking process was reduced from about an hour to a few minutes. The code developed in this work allows the user to consider the big picture, trusting the software to track details.

Clearance assurance for stereotactic radiosurgery and radiotherapy.

The nature of stereotactic radiotherapy (SRT)/radiosurgery (SRS) requires the use of oblique non-coplanar beams to avoid critical structures and maximize target coverage. These beams are delivered via a combination of gantry, collimator, and couch rotations. Such beam orientations could result in the gantry colliding with the patient or couch. The outcome can be patient injury, damaged equipment, and unrealized treatment. Our objective in this work was to create a treatment planning tool that utilizes each unique patient geometry to quantify clearance for stereotactic beams. Emphasis was placed on developing a general platform that can completely, yet easily, define any user system. Gantry components were described by providing component dimensions to software that generates thousands of surface points. Table components were described as a combination of boxes and measured surface points. During the treatment planning process isocenter coordinates, patient dimensions and beam orientation were specified. Gantry components were then transformed into the table reference frame. The shortest distance between the gantry and patient or couch was computed and compared to a safety margin. This clearance assurance algorithm was developed in response to the need to reduce patient setup time, and to increase the range of potentially useful beams. The software was verified by measuring minimum gantry-table distances at multiple beam orientations and comparing to calculations. Differences between calculated and measured clearances were on the order of 1 cm. The software enabled the safe delivery of noncoplanar oblique beams that are difficult to visualize. The software was used successfully to assure clearance for 50 patients (366 beams). This useful clinical tool became an integral part of the stereotactic quality assurance protocol at St Luke's-Roosevelt Hospital Center.

Radiation Dose Assessment for I-131 Therapy of Thyroid Cancer Using I-124 PET Imaging.

The goal for this work was to develop a method to determine the feasibility of estimating absorbed dose distribution of I-131 thyroid therapy using I-124 PET images of residual thyroid lesions with the dose constraint of 200 cGy to blood, that is a surrogate for bone marrow toxicity. A dose response study has been carried out on 3 patients with papillary thyroid carcinoma. Those patients were given 15-37 MBq of I-124 along with 74-185 MBq of I-131. PET imaging was performed 2-4 hour and then at 24 hour and either 48 hour, or 72 hour post-infusion. Lesion masses were computed from PET images using an adaptive thresholding technique. The definition of the boundary enabled determination of the iodine activity within the lesion. Time-activity curves were fitted to estimate the cumulated activity and therefore the absorbed dose per MBq administered. Daily blood and total body counts were performed on the patients using a multichannel analyzer with windows set for both I-131 (364 keV) and I-124 (511 keV). Cross-talk corrections from one isotope into the alternate window was determined using a standard of each respective isotope. At maximum-tolerated-activity (MTA) that delivers 200 cGy radiation dose to the blood, the dose to lesions from I-131 varied from 0.04 to 2.44 cGy/MBq (1.57-90.48 rads/mCi) with effective half-lives for I-124 ranging from 0.58 to 1.86 days. The three-dimensional absorbed dose distribution in the thyroid lesions was calculated by convolving the activity values with an I-131 point-source kernel using a Fast Hartley Transform. The calculated mean absorbed dose distribution was displayed as isodose lines on PET images that can be used to refine the amount of administered activity. PET with I-124 may improve the absorbed dose estimates from radioiodine therapy with I-131 in the treatment of thyroid cancer. The capability of estimating I-131 mean absorbed dose distributions from serial I-124 PET images can lead to patient-specific treatment planning for thyroid therapy.